JP2016522179A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522179A5 JP2016522179A5 JP2016509298A JP2016509298A JP2016522179A5 JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5 JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- tamoxifen
- derivative
- formula
- isomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2013-308A CZ2013308A3 (cs) | 2013-04-24 | 2013-04-24 | Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2 |
| CZPV2013-308 | 2013-04-24 | ||
| CZ2014-66A CZ305571B6 (cs) | 2014-01-29 | 2014-01-29 | Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2 |
| CZPV2014-66 | 2014-01-29 | ||
| PCT/CZ2014/000035 WO2014173374A1 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522179A JP2016522179A (ja) | 2016-07-28 |
| JP2016522179A5 true JP2016522179A5 (https=) | 2017-04-06 |
| JP6375091B2 JP6375091B2 (ja) | 2018-08-15 |
Family
ID=50677895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509298A Expired - Fee Related JP6375091B2 (ja) | 2013-04-24 | 2014-04-07 | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9896466B2 (https=) |
| EP (1) | EP2989110B1 (https=) |
| JP (1) | JP6375091B2 (https=) |
| KR (1) | KR101764991B1 (https=) |
| CN (1) | CN105452265B (https=) |
| AU (1) | AU2014256546B2 (https=) |
| CA (1) | CA2909994C (https=) |
| CY (1) | CY1120821T1 (https=) |
| DK (1) | DK2989110T3 (https=) |
| EA (1) | EA029881B1 (https=) |
| ES (1) | ES2699099T3 (https=) |
| GE (2) | GEAP201813996A (https=) |
| HR (1) | HRP20181872T1 (https=) |
| HU (1) | HUE042239T2 (https=) |
| MD (1) | MD4626C1 (https=) |
| NZ (1) | NZ713589A (https=) |
| PL (1) | PL2989110T3 (https=) |
| PT (1) | PT2989110T (https=) |
| SI (1) | SI2989110T1 (https=) |
| UA (1) | UA116469C2 (https=) |
| WO (1) | WO2014173374A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016290425A1 (en) * | 2015-07-03 | 2018-01-18 | Bayer Cropscience Aktiengesellschaft | N-(tetrazole-5-yl)- and N-(triazole-5-yl)aryl carboxamide derivatives with herbicidal action |
| US10556874B2 (en) * | 2015-07-03 | 2020-02-11 | Bayer Cropscience Aktiengesellschaft | N-(1,3,4-oxadiazol-2-yl)aryl carboxamide derivatives with herbicidal action |
| HK1257296A1 (zh) * | 2016-07-12 | 2019-10-18 | Accutar Biotechnology Inc. | 新的化合物及其用途 |
| WO2018034945A1 (en) | 2016-08-19 | 2018-02-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration |
| EP3330274A1 (en) * | 2016-12-01 | 2018-06-06 | Springtide Ventures s.r.o. | Compounds for treatment of senescence-related disorders |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| CA3060509A1 (en) | 2017-04-21 | 2018-10-25 | Federica Sotgia | Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy |
| KR20200010343A (ko) | 2017-05-19 | 2020-01-30 | 루넬라 바이오테크 인코포레이티드 | 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제 |
| RU2020116649A (ru) | 2017-10-24 | 2021-11-30 | Лунелла Байотек, Инк. | Митофлавосцины: нацеливание на флавин-содержащие ферменты устраняет злокачественные стволовые клетки (cscs) посредством ингибирования митохондриального дыхания |
| US10980821B2 (en) | 2017-11-24 | 2021-04-20 | Lunella Biotech, Inc. | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
| US11497759B2 (en) | 2017-12-01 | 2022-11-15 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| US11541120B2 (en) | 2017-12-05 | 2023-01-03 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
| EP3728300A4 (en) | 2017-12-20 | 2021-08-11 | Lunella Biotech, Inc. | TARGETING OF MITOCHONDRIAL FISSION BY MDIVI-1 DERIVATIVES |
| CA3136811A1 (en) * | 2019-04-16 | 2020-10-22 | Lunella Biotech, Inc. | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments |
| EP3753944A1 (en) | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06504522A (ja) * | 1990-10-01 | 1994-05-26 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 高親和性タモキシフェン誘導体とその使用 |
| JP3635708B2 (ja) * | 1995-03-06 | 2005-04-06 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| TWI309571B (en) * | 2002-12-31 | 2009-05-11 | Ind Tech Res Inst | Delivery carrier for targeting cells haring over-expressed estrogen |
| KR101003960B1 (ko) * | 2003-08-22 | 2010-12-30 | 안티포딘 파마슈티칼스, 인코포레이티드 | 미토콘드리아 표적화 산화방지제로서 사용되는 미토퀴논 유도체를 포함하는 약제학적 조성물 |
| CN1997403A (zh) * | 2004-07-13 | 2007-07-11 | 奥里迪斯生物医学研究及开发有限责任公司 | 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途 |
| NZ602579A (en) * | 2008-03-14 | 2013-12-20 | Stephen John Ralph | Mitochondrially delivered anti-cancer compounds |
| CA2756820A1 (en) * | 2009-04-17 | 2010-10-21 | Colby Pharmaceutical Company | Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses |
| WO2011129837A1 (en) * | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
-
2014
- 2014-04-07 PT PT14721738T patent/PT2989110T/pt unknown
- 2014-04-07 WO PCT/CZ2014/000035 patent/WO2014173374A1/en not_active Ceased
- 2014-04-07 EP EP14721738.4A patent/EP2989110B1/en active Active
- 2014-04-07 SI SI201430928T patent/SI2989110T1/sl unknown
- 2014-04-07 AU AU2014256546A patent/AU2014256546B2/en not_active Ceased
- 2014-04-07 MD MD20150117A patent/MD4626C1/ro not_active IP Right Cessation
- 2014-04-07 DK DK14721738.4T patent/DK2989110T3/en active
- 2014-04-07 EA EA201591918A patent/EA029881B1/ru unknown
- 2014-04-07 CA CA2909994A patent/CA2909994C/en active Active
- 2014-04-07 NZ NZ713589A patent/NZ713589A/en not_active IP Right Cessation
- 2014-04-07 UA UAA201510642A patent/UA116469C2/uk unknown
- 2014-04-07 HU HUE14721738A patent/HUE042239T2/hu unknown
- 2014-04-07 GE GEAP201813996A patent/GEAP201813996A/en unknown
- 2014-04-07 JP JP2016509298A patent/JP6375091B2/ja not_active Expired - Fee Related
- 2014-04-07 HR HRP20181872TT patent/HRP20181872T1/hr unknown
- 2014-04-07 US US14/786,710 patent/US9896466B2/en not_active Expired - Fee Related
- 2014-04-07 ES ES14721738T patent/ES2699099T3/es active Active
- 2014-04-07 KR KR1020157030376A patent/KR101764991B1/ko not_active Expired - Fee Related
- 2014-04-07 CN CN201480033316.9A patent/CN105452265B/zh not_active Expired - Fee Related
- 2014-04-07 PL PL14721738T patent/PL2989110T3/pl unknown
-
2015
- 2015-04-07 GE GEAP201513996A patent/GEP20186868B/en unknown
-
2018
- 2018-11-06 CY CY181101155T patent/CY1120821T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522179A5 (https=) | ||
| JP6375091B2 (ja) | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 | |
| Dwarka et al. | Identification of potential SARS-CoV-2 inhibitors from South African medicinal plant extracts using molecular modelling approaches | |
| KR20140008297A (ko) | 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체 | |
| Tang et al. | Synthesis and biological evaluation of 2, 3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2 | |
| TW202545942A (zh) | Ｃｄｋ抑制劑 | |
| Girgis et al. | Synthesis, and QSAR analysis of anti-oncological active spiro-alkaloids | |
| JP2013064024A5 (https=) | ||
| AU2022205484B2 (en) | Pyridone multiple-membered ring derivatives and use thereof | |
| JP2019519593A5 (https=) | ||
| WO2017143059A1 (en) | Max binders as myc modulators and uses thereof | |
| JP2014530181A5 (https=) | ||
| NO20061319L (no) | 5-arylpyrimidiner som anticancer legemidler | |
| Zbieg et al. | Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer | |
| JP2013523867A5 (https=) | ||
| Sahu et al. | Interaction of Ru-4′-(2-pyridyl)-2, 2′: 6′, 2 ″-terpyridine with diseased HER2 protein | |
| JP2010509306A5 (https=) | ||
| JP2019517474A5 (https=) | ||
| JP2015534958A (ja) | Ｎ−置換３，４−ビス（カテコール）ピロール化合物、その調製、及びガンの治療のためのその使用 | |
| CN102649778A (zh) | 喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 | |
| Yu et al. | Discovery of potent and orally available small molecule inhibitors of the SOS1-KRAS interaction | |
| JP2019510070A5 (https=) | ||
| HK1216317B (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| Withaferin | Integrated In silico Docking and MoMA Simulation Approaches Reveal Withaferin A, Withalongolides A and B as Potent Aldo-Keto Reductase (AKR) 1C3 Inhibitors | |
| Fernandez-Nogueira et al. | 423 Acquisition of Resistance to Anti-Her2 Therapies Promotes a Different Microenvironment Crosstalk Capability |